We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Probiotics Help Diminish Fatty Liver Deposits

By HospiMedica International staff writers
Posted on 31 Jul 2014
Print article
A new study demonstrates that the consumption of probiotics for thirty days helps diminish the accumulation of fat in the liver.

Researchers at the University of Granada (UGR; Spain) and the Hero (Alcantarilla, Spain) Global Technology Center conducted a study to evaluate the effects of probiotic strains on hepatic steatosis in obese rats. The researchers administered three strains from the Collection Nationale de Cultures de Microorganismes (CNCM) of The Pasteur Institute (Paris, France); Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035, and Lactobacillus rhamnosus CNCM I-4036.

The strains were administered for thirty days to Zucker rats, who develop obesity due to a mutation in the gene that codifies the receptor of leptin, a hormone that transmits a sensation of satiety to the organism. The results showed that the administration of probiotics led to an accumulation of triacylglycerides in the liver which was significantly lower than that occurring in rats fed with a placebo. The rats fed with probiotics also had lower serum values of proinflamatory molecules such as tumor-a necrosis factor, interleukin 6, and lipopolysaccharide (LPS). The study was published on May 22, 2014, in PLOS ONE.

“The probiotic strains reduced hepatic steatosis in part by lowering serum LPS, and had an anti-inflammatory effect in obese Zucker rats. This is a step forward on the fight against non-alcolohic fatty liver disease,” concluded lead author Julio Plaza-Diaz, MSc, and colleagues of the UGR José Mataix Institute for Nutrition and Food Technology. “Liver disease will not be cured with probiotics, but these microorganisms can certainly be used as support therapy in joint use with other treatments.”

Non-alcolohic fatty liver disease (NAFLD) is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g., diabetes mellitus type 2) such as weight loss, metformin, and thiazolidinediones. For most people, it causes no signs, symptoms, or complications, but in some cases accumulated fat can cause inflammation and scarring in the liver, called nonalcoholic steatohepatitis, a major cause of cirrhosis of the liver of unknown cause.

Probiotics are microorganisms that provide health benefits; they are commonly consumed live as part of fermented foods such as in yogurt, or in dietary supplements. The introduction of the concept is generally attributed to Nobel Prize recipient Eli Metchnikoff, who in 1907 suggested that "the dependence of the intestinal microbes on the food makes it possible to adopt measures to modify the flora in our bodies and to replace the harmful microbes by useful microbes.”

Related Links:

University of Granada
Hero
The Pasteur Institute


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Vein Illuminator
VSI

Print article

Channels

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.